paclitaxel + vinorelbine + carboplatin + bevacizumab

A non-branded combination chemotherapy regimen consisting of paclitaxel, vinorelbine, carboplatin, and bevacizumab. - **Paclitaxel** is a microtubule-stabilizing agent (taxane) inhibiting mitosis, used as an antineoplastic in various solid tumors. - **Vinorelbine** is a vinca alkaloid that inhibits microtubule formation, thereby blocking cell division. - **Carboplatin** is a platinum-based agent that induces DNA crosslinking and apoptosis in tumor cells. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This combination is not a standard, fixed combination but has been investigated or used in advanced or metastatic cancer, especially non-small-cell lung cancer and potentially breast or gynecological cancers, where combination chemotherapy with angiogenesis inhibition is pursued. Paclitaxel and carboplatin with bevacizumab is a widely studied, approved regimen in several cancers; vinorelbine can be substituted or added for refractory or pretreated cases. Mechanisms are additive/synergistic: cytotoxic action (paclitaxel, vinorelbine, carboplatin) plus inhibition of new vessel formation/growth (bevacizumab). Bevacizumab is typically included to enhance chemotherapy delivery and tumor response through vascular normalization. Empirical data on the four-drug combination are sparse; most trials report on dual or triple combinations from these drugs[1][3][6][7].

Other names

paclitaxel + vinorelbine + carboplatin + bevacizumab